循环核化酶10A在病态心脏重塑和功能障碍中的新型作用
Si Chen1,2, Yishuai Zhang1, Janet K Lighthouse1
1Aab Cardiovascular Research Institute, Department of Medicine (S.C., Y.Z., J.K.L., D.M.M., J.W., P.Y., E.M.S., C.Y.), University of Rochester School of Medicine and Dentistry, NY.
Circulation
|December 6, 2019
概括
固酶10A (PDE10A) 在心力衰竭中被上调,并驱动病态心脏重塑. 使用TP-10抑制PDE10A可以逆转心脏功能障碍和纤维化,这表明PDE10A抑制是潜在的心力衰竭治疗方法.
科学领域:
- 心血管生物学
- 分子心脏病学
- 药理学
背景情况:
- 心脏衰竭是全球的主要健康问题.
- 循环核酸酶 (PDEs) 调节心血管功能.
- 在患病的心脏中,PDE10A的调节升高,但其作用尚不清楚.
研究的目的:
- 研究心脏细胞中的PDE10A调节和功能.
- 确定PDE10A在心脏重塑和功能障碍进展中的作用.
主要方法:
- 使用成年小鼠心肌细胞和纤维细胞.
- 使用心脏缩和心力衰竭的临床前小鼠模型.
- 使用PDE10A选择性抑制剂TP-10和全球PDE10A淘汰的小鼠.
主要成果:
- 在衰弱的人和老鼠的心脏中,PDE10A的调节升高.
- 抑制PDE10A减弱了病态心脏缩和纤维化.
- PDE10A 缺乏可以逆转先前确定的心脏缩和功能障碍.
结论:
- 在病理性心脏重塑中,PDE10A起着新的作用.
- 抑制PDE10A是一种潜在的治疗心力衰竭策略.
- 向PDE10A可以预防和治疗心脏重塑相关的疾病.
相关概念视频
Heart Failure II: Pathophysiology
624
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
624
Cardiomyopathy III: Hypertrophic Cardiomyopathy
325
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
325
Cardiomyopathy II: Dilated Cardiomyopathy
405
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
405
Transducer Mechanism: Enzyme-Linked Receptors
3.8K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
3.8K
Cardiomyopathy V: Interprofessional Care
282
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
282
Pathophysiology of Heart Failure
2.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.6K


